Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : a multicentre, open-label, randomised, phase 3 trial

DSpace Repository

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : a multicentre, open-label, randomised, phase 3 trial

Author: Dummer, Reinhard; Ascierto, Paolo A.; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Sileni, Vanna Chiarion; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A.; Pickard, Michael D.; Sandor, Victor; Roberti, Caroline; Flaherty, Keith T.
Tübinger Autor(en):
Garbe, Claus
Published in: Lancet Oncology (2018), Bd. 19, H. 10, S. 1315-1327
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(18)30497-2
ISSN: 1474-5488
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)